Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc. (Nasdaq: TVGN) is a clinical-stage biopharmaceutical company specializing in T-cell immunotherapy for infectious diseases and oncology that entered public markets through a SPAC merger in 2022. The company filed its quarterly report on Form 10-Q with the Securities and Exchange Commission on November 14, 2022, accession number 0001410578-22-003394, reflecting its operating status as a newly combined public entity in the life sciences sector. Tevogen Bio is advancing a proprietary engineered T-cell therapy platform targeting viral infections and cancer, with its programs in early-stage clinical development at the time of the filing. For comprehensive filing timelines, SPAC deal analytics, and full data on TVGN, create a free account at SpacDesk.